SCHEMBL5501377

SCHEMBL5501377

CN1CCc2cc(O)ccc21

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 9/20 0.56
DRD1 P21728 9/20 0.56
DRD5 P21918 8/20 0.56
DRD3 P35462 8/20 0.56
DRD4 P21917 6/20 0.50
MAPT P10636 2/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
HPGD P15428 1/20 0.45
KMT2A Q03164 1/20 0.45
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
NOTUM Q6P988 2/20 0.43
WDR5 P61964 1/20 0.43
NPC1 O15118 1/20 0.43
TP53 P04637 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP3A4 P08684 1/20 0.43
CYP2D6 P10635 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3178012 0.89 MEN1 (0.58) DRD2DRD1DRD5DRD3DRD4
SCHEMBL13957123 0.85 WDR5 (0.49) DRD2DRD1DRD5DRD3MAPT
SCHEMBL93622 0.84 DRD1 (0.56) DRD2DRD1DRD5DRD3DRD4
Hydrochloric Acid SCHEMBL11027184 0.82 DRD1 (0.55) DRD2DRD1DRD5DRD3DRD4
SCHEMBL2625777 0.80 NOTUM (0.57) MAPTMEN1ALDH1A1GAAHPGD
SCHEMBL2616784 0.79 NOTUM (0.58) MAPTMEN1ALDH1A1GAAHPGD
SCHEMBL2333530 0.78 MAPT (0.49) DRD1MAPTMEN1ALDH1A1GAA
SCHEMBL3154176 0.78 MAPT (0.49) DRD1MAPTMEN1ALDH1A1GAA
Bromomethane SCHEMBL3499030 0.77 NOTUM (0.54) MAPTMEN1ALDH1A1GAAHPGD
SCHEMBL2625779 0.76 NOTUM (0.57) MAPTMEN1ALDH1A1GAAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11136338-B2 Fused thiazolopyrimidine derivatives as MNKs inhibitors LIFEARC (GB) 2021-10-05 US disclosed
EP-3377501-B1 FUSED THIAZOLOPYRIMIDINE DERIVATIVES AS MNKS INHIBITORS LIFEARC (GB) 2021-08-18 EP disclosed
US-20200247822-A1 Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors ASTRAZENECA UK LIMITED (GB) 2020-08-06 US disclosed
US-10669284-B2 Fused thiazolopyrimidine derivatives as MNKS inhibitors LIFEARC (GB) 2020-06-02 US disclosed
US-20180271924-A1 COMPOUND AND METHOD FOR REDUCING INFLAMMATION, PAIN, ALLERGY, FLU AND COLD SYMPTOMS KARIMAN ALEXANDER (US) 2018-09-27 US disclosed
CN-102498095-A Indoline derivatives TOKYO INST TECH 2012-06-13 CN disclosed
US-8110575-B2 Compounds BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-02-07 US disclosed
EP-2394990-A1 INDOLINE DERIVATIVES Kyoto University (JP) 2011-12-14 EP disclosed
US-20110294850-A1 INDOLINE DERIVATIVES TOKYO INSTITUTE OF TECHNOLOGY (JP) 2011-12-01 US disclosed
US-20110021500-A1 NOVEL COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-01-27 US disclosed
EP-1950199-B1 Proline derivatives and use thereof as drugs MITSUBISHI TANABE PHARMA CORP (JP) 2009-12-02 EP disclosed
WO-2009100872-A1 UREA DERIVATIVES OF BENZOMORPHANES AND RELATED SCAFFOLDS, MEDICAMENTS CONTAINING SUCH COMPOUNDS AND THEIR USE BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-08-20 WO disclosed
EP-1308439-B1 PROLINE DERIVATIVES AND USE THEREOF AS DRUGS MITSUBISHI TANABE PHARMA CORP (JP) 2008-10-15 EP disclosed
EP-1791807-A1 THERAPEUTIC DIPHENYL ETHER LIGANDS Pfizer Products Incorporated (US) 2007-06-06 EP disclosed
WO-2006027684-A1 THERAPEUTIC DIPHENYL ETHER LIGANDS PFIZER PRODUCTS INC. (US) 2006-03-16 WO disclosed
US-20060058361-A1 Therapeutic diphenyl ether ligands PFIZER INC 2006-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021500-A1 NOVEL COMPOUNDS CALCRL, CALCR, CALCA DRD2 640/4885DRD1 728/4885DRD5 1111/4885
US-20200247822-A1 Fused Thiazolopyrimidine Derivatives As MNKS Inhibitors MAPT, TTBK1, TTBK2 DRD2 4838/4885DRD1 4818/4885DRD5 4668/4885
US-20110294850-A1 INDOLINE DERIVATIVES BCHE, ACHE, INMT DRD2 289/4885DRD1 343/4885DRD5 461/4885
US-11136338-B2 Fused thiazolopyrimidine derivatives as MNKs inhibitors MAPT, TTBK1, TTBK2 DRD2 4838/4885DRD1 4818/4885DRD5 4668/4885
US-10669284-B2 Fused thiazolopyrimidine derivatives as MNKS inhibitors MAPT, TTBK1, TTBK2 DRD2 4843/4885DRD1 4825/4885DRD5 4694/4885
US-20060058361-A1 Therapeutic diphenyl ether ligands HTR2B, HTR2C, HTR3B DRD2 137/4885DRD1 370/4885DRD5 548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.